Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine filings document the regulatory and financial record of a clinical-stage biopharmaceutical company developing hematologic disease therapies. Its Form 8-K disclosures cover quarterly and annual financial results, corporate updates, clinical-program materials for bitopertin, DISC-0974 and DISC-3405, and FDA communications related to the bitopertin New Drug Application for erythropoietic protoporphyria.
The filing record also includes proxy materials covering board matters, executive compensation and shareholder voting items. Material-event reports describe Regulation FD presentations, operating runway disclosures, restructuring actions following regulatory developments, and risk-related statements around clinical trials, regulatory pathways, research spending and capital resources.
SEC Form 4 filing (07/25/2025) discloses that Disc Medicine (IRON) director Kevin Bitterman executed two open-market sales through affiliated Atlas Venture funds.
- 07/23/2025: 29,837 common shares sold at a weighted-average price of $60.97.
- 07/24/2025: 13,033 common shares sold at a weighted-average price of $61.17.
Following the transactions, Bitterman’s indirect ownership via Atlas funds decreased from roughly 676,839 to 633,969 shares. He also continues to hold an additional 420,549 shares in Opportunity II and 51,000 shares in Atlas XII, keeping his total indirect stake above 1.1 million shares. Bitterman remains a board member and reports no derivative activity.
Disc Medicine, Inc. (IRON) – Form 4 insider transaction
Chief Financial Officer Jean M. Franchi disclosed the sale of 2,000 common shares on 07/10/2025 at $57.50 per share, for proceeds of roughly $115 thousand. The transaction was executed under a Rule 10b5-1 trading plan adopted on 03/10/2025, indicating it was pre-scheduled rather than discretionary. After the sale, Franchi retains 65,530 shares, a decrease of about 3% of her direct holdings, maintaining a sizable equity position that continues to align her interests with shareholders. No derivative securities acquisitions or dispositions were reported in this filing.
Disc Medicine, Inc. (Nasdaq: IRON) has filed a Form 8-K announcing the election of Nadim Ahmed to its Board of Directors, effective 14 July 2025. Ahmed will serve as a Class I director until the company’s 2027 annual meeting and thereafter until a successor is elected or he resigns. Under the company’s non-employee director compensation policy, he will receive $40,000 in annual cash fees (paid $10,000 quarterly) and a non-statutory option for 20,000 shares of common stock priced at the market close on the effective date. The option vests one-third on the first anniversary and the balance in equal monthly installments over the next two years, contingent on continued service. The filing notes no related-party transactions involving Ahmed and states he will enter into the standard director indemnification agreement. No other material financial or operational disclosures were provided.